Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 28 for your search:
Drug:
yttrium Y 90 ibritumomab tiuxetan
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Study of Yttrium Y 90-Labeled Ibritumomab Tiuxetan With Rituximab in Patients With B-Cell Non-Hodgkin's Lymphoma Who Have Relapsed After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
19 and over
Sponsor:
Other
Protocol IDs:
UNMC-535-00
, NCI-V02-1691, NCT00031642
2.
Phase I/II Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Patients With Post-Transplant Lymphoproliferative Disorder
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
AMC-037
, NCT00064246
3.
Phase I/II Study of Motexafin Gadolinium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Bulky Stage II or Stage III or IV Relapsed or Refractory CD20-Positive Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NU-02H8
, NU-0228-024, PCI-P-PCYC-0213, NCT00089284
4.
Phase I/II Study of Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NU-05H9
, NU-0522-060, MILLENNIUM-NU-05H9, NCT00372905
5.
Phase I/II Study of CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With CD20+ Recurrent or Refractory Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-LS0382
, MAYO-IRB-703-04, NCT00438880
6.
Radioimmunotherapy With 90Y-Ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
2005-002206-37
, NCT00302757
7.
Phase I/II Study of Yttrium Y 90 Ibritumomab Tiuxetan in Combination With High-Dose Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Patients With Poor-Risk, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 to 60
Sponsor:
NCI
Protocol IDs:
CHNMC-98153
, 98153, NCT00562978
8.
Phase II Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Patients Age 60 and Over With Previously Untreated Diffuse Large B-Cell Lymphoma
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Closed
Age:
60 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-02090
, NCT00058422
9.
Phase II Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Patients With Transformed CD20+ B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-50201
, NCT00062114, SWOG-C50201, ECOG-C50201
10.
Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone and Radiotherapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Aggressive High-Risk Stage I or IE or Non-Bulky Stage II or IIE CD20-Positive Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
SWOG-S0313
, S0313, NCT00070018
11.
Phase II Study of Rituximab and CHOP Chemotherapy Comprising Prednisone, Cyclophosphamide, Doxorubicin, and Vincristine Followed By Yttrium Y 90 Ibritumomab Tiuxetan (Yttrium Y 90 Zevalin®) in Patients With Previously Untreated Mantle Cell Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-E1499
, E1499, NCT00070447
12.
Study Of Yttrium-Ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
ID01-541
, NCT00038623
13.
Phase II Study of Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, and Vincristine Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Stage I or II CD20-Positive Diffuse Large Cell Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-E3402
, E3402, NCT00088881
14.
Phase II Study of a Nonmyeloablative Conditioning Regimen Comprising Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, and Low-Dose Total-Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
FHCRC-1726.00
, 5787, NCT00119392
15.
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
04-251
, NCT00119730
16.
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
Z-BEAM
, NCT00138086
17.
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
Over 18
Sponsor:
Other
Protocol IDs:
SCRI LYM 27
, 106-P092, NCT00193505
18.
Autologous Stem Cell Transplantation (ASCT) With Zevalin Plus Busulfan, Cyclophosphamide and Etoposide (BuCyE) in B-Cell Non-Hodgkin's Lymphoma (NHL)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
64 and under
Sponsor:
Other
Protocol IDs:
AMC 2005-276
, NCT00336843
19.
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2005-0571
, NCT00493454
20.
Phase I Study of Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, and Autologous Peripheral Blood Stem Cell Rescue in Patients With Indolent or Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 to 70
Sponsor:
NCI
Protocol IDs:
JHOC-J0004
, J0004, NCI-970, 970, NCT00017381
21.
Phase I Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed CD20-Positive B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
19 and over
Sponsor:
NCI
Protocol IDs:
UAB-0127
, UAB-F010806018, NCI-G02-2053, NCT00033423
22.
Phase I Study of Rituximab Followed By Yttrium Y 90 Ibritumomab Tiuxetan With or Without Autologous Peripheral Blood Stem Cell Transplantation in Children With Recurrent or Refractory CD20-Positive Lymphoma
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
Under 22
Sponsor:
NCI
Protocol IDs:
COG-ADVL0013
, NCT00036855, ADVL0013
23.
Phase I Study of Yttrium Y 90 Ibritumomab Tiuxetan and High-Dose Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
Over 17
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NU-99H11
, IDEC-NU99H11, NCT00058292
24.
Phase I Study of Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Waldenstrom's Macroglobulinemia
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
Over 18
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UCLA-0202063
, IDEC-UCLA-0202063, NCT00060294
25.
90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
18 to 70
Sponsor:
NCI, Other
Protocol IDs:
BMT134
, 80109, BMT134, NCT00186589, NCT00186589
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
